Siglec 9 for the diagnosis of ARDS

项目摘要/摘要 急性呼吸窘迫综合征(ARDS)占重症监护室10%的入院人数和30%的死亡人数 护理室。尽管进行了广泛的基础和临床研究，但ARDS患者的住院死亡率仍为 高达45%。缺乏有效疗法的主要原因包括缺乏工具来预测 患者会发展成ARDS，很难与其他导致肺水肿的原因区分开来 比如充血性心力衰竭(CHF)。由于这种诊断的不确定性，只有不到一半的ARDS病例是 在全球范围内，针对ARDS的治疗未得到充分利用的比例为25%。使用来自美国的 液体和导管治疗试验(自由液体与保守液体的随机对照试验 管理)对ARDS患者的治疗，以及对保留心功能心力衰竭的治疗 醛固酮拮抗剂试验(安体舒通治疗心力衰竭患者的随机试验 射血分数)，我们将在目标1中确定血清Siglec-9在ARDS和CHF之间的区分程度 在AIM 2中，Siglec-9水平与ARDS严重程度和临床预后相关。这项工作的结果是 使ARDS患者的早期诊断、治疗和预后评估成为可能的巨大潜力。

Project Summary/Abstract Acute respiratory distress syndrome (ARDS) accounts for 10% of admissions and 30% of mortality in intensive care units. Despite extensive basic and clinical research, hospital mortality for patients with ARDS remains as high as 45%. Major reasons for the lack of effective therapies include the lack of tools for predicting which patients will develop ARDS and the difficulty of differentiating ARDS from other causes of pulmonary edema like congestive heart failure (CHF). Because of such diagnostic uncertainty, fewer than half of ARDS cases are recognized, and ARDS-specific therapies are underutilized by 25% worldwide. Using plasma samples from the Fluid and Catheter Treatment Trial (a randomized controlled trial of liberal versus conservative fluid management) in patients with ARDS, and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial (a randomized trial of spironolactone in patients with heart failure with preserved ejection fraction), we will in AIM 1 determine how well serum Siglec-9 distinguishes between ARDS and CHF and in AIM 2 Correlate Siglec-9 levels with ARDS severity and clinical outcomes. The results of this work have tremendous potential to enable earlier diagnosis, treatment, and prognostic assessment of patients with ARDS.